Connect Biopharma Holdings Ltd ADR (CNTB) Stock Price, Quote & News

Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquarte...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1040

Website: www.connectbiopharm.com

Address:

3580 CARMEL MOUNTAIN ROAD, SUITE 200, San Diego, United States

BillionerOfKing Feb. 20 at 11:32 PM

$CNTB Current Stock Price: $2.67 Contracts to trade: $2.5 CNTB Feb 20 2026 Call Entry: $0.48 Exit: $0.87 ROI: 81% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ReturnStacking Feb. 20 at 1:29 PM

$CNTB Centessa Pharmaceuticals develops immunology and oncology assets. Valuation is driven by clinical milestones. Portfolio diversification reduces single-asset risk.

0 · Reply

GreyVolume Feb. 18 at 8:17 AM

$CNTB Connect Biopharma develops immunology therapies, facing early-stage pipeline with promising but competitive landscape [citation:historical].

0 · Reply

topstockalerts Feb. 17 at 8:24 PM

$CNTB Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.

0 · Reply

BioCurious1 Feb. 17 at 6:37 PM

$CNTB gonna be a big first half in 2026 with P1b data coming in the next few weeks Paired with the Phaee 2 Trial Data mid year. Low visibility currently , curious to see how it develops over the next few months. Hoping for an 100% gain here

1 · Reply

PortfolioOverture Feb. 17 at 2:24 PM

$CNTB Connect Biopharma advancing rademikibart for asthma/COPD with unique MOA data; Phase 1b results expected Q1 2026 and Seabreeze studies mid-2026; cash runway into 2027.

0 · Reply

ScalperZed Feb. 17 at 8:53 AM

$CNTB Pre-revenue biotech; early-stage

0 · Reply

BioCurious1 Feb. 11 at 5:37 PM

$CNTB 10 day vol average has been super low. 60k-70k shares being traded. Set for a big move when this reports mid year, potentially earlier with phase 1b results coming in the next few weeks. Personally bullish, but going to be a big move one way or the other

0 · Reply

BioCurious1 Feb. 6 at 3:30 PM

$CNTB this is going to fly or tank depending on the news. When I bought shares it legit moved the price 5%. I’ve never seen something move so fragile with a purchase under 25k

2 · Reply

NVDAMillionaire Feb. 4 at 1:49 PM

$CNTB Excellent article that nails exactly where CNTB stands right now. So if you want to update your CNTB knowledge or get acquainted with CNTB, this is a must read. https://everyticker.com/quote/CNTB/analysis/connect-biopharma-betting-on-rademikibart-s-acute-respiratory-potential-cntb

0 · Reply

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 12, 2026, 8:00 AM EST - 6 weeks ago

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

Nov 24, 2025, 9:00 AM EST - 3 months ago

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 9:00 AM EST - 3 months ago

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 9:36 PM EST - 3 months ago

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Sep 29, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Aug 27, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Aug 14, 2025, 8:00 AM EDT - 6 months ago

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Aug 13, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Jul 21, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Jul 18, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Jul 17, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 13, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

May 28, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 20, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 15, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 13, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Apr 24, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 1, 2025, 9:00 AM EDT - 11 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Mar 31, 2025, 4:05 PM EDT - 11 months ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 9:00 AM EDT - 11 months ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 28, 2025, 4:05 PM EDT - 11 months ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 3, 2025, 8:00 AM EST - 1 year ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Attovia Therapeutics Appoints Chief Financial Officer

Oct 9, 2024, 3:55 PM EDT - 1 year ago

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 2, 2024, 4:14 PM EDT - 1 year ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jun 12, 2024, 6:03 PM EDT - 1 year ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 4:15 PM EDT - 1 year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

May 22, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 1 year ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Apr 16, 2024, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 12, 2024, 4:30 PM EST - 2 years ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Dec 12, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 11, 2023, 4:05 PM EST - 2 years ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Nov 21, 2023, 6:03 AM EST - 2 years ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 20, 2023, 4:41 PM EST - 2 years ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Sep 12, 2023, 4:15 PM EDT - 2 years ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 6:00 AM EDT - 2 years ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Aug 24, 2023, 6:21 PM EDT - 2 years ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

BillionerOfKing Feb. 20 at 11:32 PM

0 · Reply

ReturnStacking Feb. 20 at 1:29 PM

$CNTB Centessa Pharmaceuticals develops immunology and oncology assets. Valuation is driven by clinical milestones. Portfolio diversification reduces single-asset risk.

0 · Reply

GreyVolume Feb. 18 at 8:17 AM

$CNTB Connect Biopharma develops immunology therapies, facing early-stage pipeline with promising but competitive landscape [citation:historical].

0 · Reply

topstockalerts Feb. 17 at 8:24 PM

$CNTB Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.

0 · Reply

BioCurious1 Feb. 17 at 6:37 PM

1 · Reply

PortfolioOverture Feb. 17 at 2:24 PM

$CNTB Connect Biopharma advancing rademikibart for asthma/COPD with unique MOA data; Phase 1b results expected Q1 2026 and Seabreeze studies mid-2026; cash runway into 2027.

0 · Reply

ScalperZed Feb. 17 at 8:53 AM

$CNTB Pre-revenue biotech; early-stage

0 · Reply

BioCurious1 Feb. 11 at 5:37 PM

0 · Reply

BioCurious1 Feb. 6 at 3:30 PM

$CNTB this is going to fly or tank depending on the news. When I bought shares it legit moved the price 5%. I’ve never seen something move so fragile with a purchase under 25k

2 · Reply

NVDAMillionaire Feb. 4 at 1:49 PM

0 · Reply

BioCurious1 Feb. 2 at 9:13 PM

$SGMT and $CNTB prob some of the best bio plays in 2026

2 · Reply

Finanz Jan. 29 at 6:37 PM

$CNTB Chart

0 · Reply

BillionerOfKing Jan. 16 at 1:00 AM

$CNTB Current Stock Price: $2.27 Contracts to trade: $5 CNTB Jan 16 2026 Call Entry: $0.09 Exit: $0.13 ROI: 48% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

DMaulST Jan. 13 at 3:17 PM

$CNTB picked up some shares this morning, 2026 should be good

0 · Reply

Mtango Jan. 6 at 5:55 PM

$CNTB dos anyone have access to any of the Wall Street research on this stock?

0 · Reply

SuburbanStox Dec. 25 at 11:19 AM

$CNTB Forward risk‑reward now depends less on headlines and more on execution depth across functions. Execution reliability across quarters will determine whether confidence can compound. Successful iteration can create optionality that is not yet fully priced. The market will respond to evidence, not speculation.

0 · Reply

rombrento Dec. 24 at 10:02 PM

$CNTB

0 · Reply

jacksparo Dec. 24 at 4:31 PM

$CNTB Nice trade here done! ✅✅📈✅✅📈!

0 · Reply

herousa Dec. 23 at 3:19 AM

$LAES $OCGN $CNTB The only one in Stocktwits I followed and made money with was @jacksparo, who deserves an end-of-the-year medal for his great calls.

3 · Reply

herousa Dec. 23 at 2:55 AM

$CNTB Made 3 k here thanks to your email

0 · Reply

SuperGreenToday Dec. 22 at 6:19 PM

$CNTB Share Price: $2.52 Contract Selected: Jun 18, 2026 $2.5 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.82 – $1.00 Potential Upside: 66% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

jacksparo Dec. 22 at 4:55 PM

$CNTB It got to my lowest suggested entry levels and below last week. Today up ⬆️✅✅✅! Easy trade!

0 · Reply

Market Cap	148.15M
Revenue (ttm)	26.03M
Net Income (ttm)	-15.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60.05%
Debt to Equity Ratio	0.00

Volume	81,200
Avg Vol	97,144
Day's Range	N/A - N/A
Shares Out	55.90M
Stochastic %K	36%
Beta	-0.20
Analysts	Strong Sell
Price Target	$7.90